Cdymax (India) Pharma Private Limited – FDA 483, Apr 25, 2025
Cydmax (India) Pharma Private Limited, an API manufacturer in Jigani, Bangalore, received a Form 483 with significant observations related to quality control, laboratory practices, and manufacturing controls. The inspection revealed critical issues including inadequate investigations into out-of-specification results, unvalidated test methods, deficient quality unit oversight, and poor contamination control during API manufacturing and equipment cleaning. These findings indicate a systemic lack of adherence to cGMP regulations, posing a risk to product quality and patient safety.
ID · 6a4e0715-7b86-4b4f-9b03-429b9b408bdd
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.